Skip to main content
. 2022 May 30;15:597–608. doi: 10.2147/OTT.S352619

Table 1.

Clinicopathological Features of EGFR Mutant and EGFR Wild Type Patients Between Training Cohort and Test Cohort

Clinicopathological Features Training Cohort Test Cohort
Total (n = 176) EGFR Mutant (n = 97) EGFR Wild Type (n = 79) P value Total (n = 57) EGFR Mutant (n = 32) EGFR Wild Type (n = 25) P value
Age (Mean ± SD), years 58.9 ± 10.3 59.6 ± 9.3 58 ± 11.4 0.2896 56.1 ± 8.9 56.1 ± 9 54.3 ± 8.7 0.6233
Gender 0.0014** 0.033*
Male 99(56.3) 44(45.4) 55(69.6) 29(50.9) 12(37.5) 17(68)
Female 77(43.7) 53(54.6) 24(30.4) 28(49.1) 20(62.5) 8(32)
Smoking status 0.0034** 0.024*
Never-smoker 129(73.3) 80(82.5) 49(62) 39(68.4) 26(81.3) 13(52)
Former or current smoker 47(26.7) 17(17.5) 30(38) 18(31.6) 6(18.7) 12(48)
TNM Staging 0.3835 0.0287*
I 74(42) 42(26.7) 32(26.7) 33(57.9) 18(56.3) 15(60)
II 16(9.1) 9(26.7) 7(26.7) 4(7) 4(12.5) 0(0)
III 20(11.4) 14(26.7) 6(26.7) 7(12.3) 6(18.7) 1(4)
IV 66(37.5) 32(26.7) 34(26.7) 13(22.8) 4(12.5) 9(36)
Maximum diameter 0.0099** >0.9999
≥3cm 59(33.5) 24(24.7) 35(44.3) 12(21.1) 7(21.9) 5(20)
<3cm 117(66.5) 73(75.3) 44(55.7) 45(78.9) 25(78.1) 20(80)
Location 0.0546 0.2494
Right upper lobe 57(32.4) 40(41.2) 17(21.5) 23(40.4) 17(53.1) 6(24)
Right middle lobe 8(4.5) 4(4.1) 4(5.1) 2(3.5) 1(3.1) 1(4)
Right lower lobe 32(18.2) 15(15.5) 17(21.5) 11(19.3) 5(15.6) 6(24)
Left upper lobe 57(32.4) 29(29.9) 28(35.4) 11(19.3) 4(12.5) 7(28)
Left lower lobe 22(12.5) 9(9.3) 13(16.5) 10(17.5) 5(15.6) 5(20)
Growth pattern <0.0001*** 0.0145*
Lepidic 16(9.1) 14(14.4) 2(2.5) 5(8.8) 4(12.5) 1(4)
Acinar 90(51.1) 60(61.9) 30(38) 27(47.4) 15(46.9) 12(48)
Papillary 31(17.6) 15(15.5) 16(20.3) 12(21) 10(31.2) 2(8)
Solid 39(22.2) 8(8.2) 31(39.2) 13(22.8) 3(9.4) 10(40)

Notes: The P value represents the univariate association between each of clinical features and EGFR mutation. Data are presented as n, or n (%), except where otherwise noted. *P<0.05; **P<0.01; ***P<0.0001.